Drug Trial Radar · NCT00002378
A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients
Last checked: Nov 19, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
825
Actual
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the proportion of patients whose plasma HIV-1 RNA level falls below the level of detection (\< 400 copies/ml) at week 24 of study therapy. To determine the absolute change in plasma HIV-1 RNA during the 24 weeks of study treatment. To collect safety data on the treatment regimens. AS PER AMENDMENT 12/12/97: To compare the virologic response of Fortovase (FTV) (Saquinavir) Soft Gel Capsule (SGC) tid plus nucleoside reverse transcriptase inhibitors (NRTIs) versus FTV bid plus NRTIs. Further, to compare the virologic response of FTV tid plus NRTIs versus FTV bid plus Nelfinavir bid plus a NRTI with respect to: the percentage of patients whose plasma HIV-1 RNA level falls below the Amplicor assay level of detection (\< 400 copies/ml) at week 24 and week 48.
Conditions
- HIV Infections
Interventions
RitonavirDrug
Nelfinavir mesylateDrug
SaquinavirDrug
Delavirdine mesylateDrug
LamivudineDrug
StavudineDrug
ZidovudineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
102 sites in 6 countries. Site status is shown where the registry gives one.
ASC Inc
Anniston, Alabama
CIGNA
Phoenix, Arizona
Arizona Clinical Research Ctr Inc
Tucson, Arizona
Univ of Arizona
Tucson, Arizona
Alta Bates Med Ctr
Berkeley, California
Ctr for Special Immunology
Irvington District, California
AIDS Healthcare Foundation Labs
Los Angeles, California
Beer Med Group
Los Angeles, California
Dr Charles Farthing
Los Angeles, California
Gottlieb Med Group
North Hollywood, California
Dr Wilbert Jordan
Paramount, California
AIDS Community Research Consortium
Redwood City, California
Dr Daniel Pearce
San Francisco, California
UCSF - San Francisco Gen Hosp
San Francisco, California
Kaiser Permanente Med Ctr
San Francisco, California
QUEST Clinical Research
San Francisco, California
Marin County Specialty Clinic
San Rafael, California
Shared Med Research Foundation
Tarzana, California
Denver Public Health Dept / Disease Control Services
Denver, Colorado
Kaiser Permanente, Infectious Disease
Denver, Colorado
Georgetown Univ Med Ctr
Washington D.C., District of Columbia
Anderson Clinical Research
Washington D.C., District of Columbia
Providence Hosp
Washington D.C., District of Columbia
IDC Research Initiative
Altamonte Springs, Florida
Urgent Care Ctr
Fort Lauderdale, Florida
Stratogen of Ft Lauderdale
Fort Lauderdale, Florida
Dr Robert Schwartz
Fort Myers, Florida
Duval County Health Dept
Jacksonville, Florida
Steinhart Medical Associates
Miami, Florida
Stratogen Health of Palm Beach
Palm Beach Gardens, Florida
Ctr for Quality Care
Tampa, Florida
Univ of South Florida
Tampa, Florida
Infectious Disease Research Institute Inc
Tampa, Florida
Treasure Coast Infectious Disease Consultants
Vero Beach, Florida
AIDS Research Consortium of Atlanta
Atlanta, Georgia
Infectious Disease Specialists of Atlanta
Decatur, Georgia
Northwestern Univ Med Ctr
Chicago, Illinois
SIU School of Medicine
Springfield, Illinois
Carle Clinic Association
Urbana, Illinois
Indiana Univ Hosp
Indianapolis, Indiana
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.